Organogenesis Holdings Inc. Reports Preliminary Revenue Results for First Quarter 2020
08 avr. 2020 16h05 HE
|
Organogenesis Holdings Inc.
Withdraws Fiscal Year 2020 Revenue GuidanceAnnounces May 11, 2020 Earnings Conference Call CANTON, Mass., April 08, 2020 (GLOBE NEWSWIRE) -- Organogenesis Holdings Inc. (Nasdaq: ORGO), a leading...
Organogenesis To Sponsor March 26 Webinar, “Taking Control of the Wound Healing Environment,” Featuring Dr. Alisha Oropallo
25 mars 2020 09h15 HE
|
Organogenesis Holdings Inc.
CANTON, Mass., March 25, 2020 (GLOBE NEWSWIRE) -- Organogenesis Holdings Inc. (Nasdaq: ORGO), a leading regenerative medicine company focused on the development, manufacture, and commercialization...
Organogenesis Holdings Inc. Reports Fourth Quarter and Fiscal Year 2019 Financial Results; Introduces Fiscal Year 2020 Revenue Guidance
09 mars 2020 16h05 HE
|
Organogenesis Holdings Inc.
CANTON, Mass., March 09, 2020 (GLOBE NEWSWIRE) -- Organogenesis Holdings Inc. (Nasdaq: ORGO), a leading regenerative medicine company focused on the development, manufacture, and commercialization...
Organogenesis Holdings Inc. to Present at the 9th Annual SVB Leerink Global Healthcare Conference
21 févr. 2020 07h30 HE
|
Organogenesis Holdings Inc.
CANTON, Mass., Feb. 21, 2020 (GLOBE NEWSWIRE) -- Organogenesis Holdings Inc. (Nasdaq: ORGO), a leading regenerative medicine company focused on the development, manufacture, and commercialization of...
Organogenesis Holdings Inc. to Report Fourth Quarter and Fiscal Year 2019 Financial Results on March 9, 2020
23 janv. 2020 16h05 HE
|
Organogenesis Holdings Inc.
CANTON, Mass., Jan. 23, 2020 (GLOBE NEWSWIRE) -- Organogenesis Holdings Inc. (Nasdaq: ORGO), a leading regenerative medicine company focused on the development, manufacture, and commercialization of...
Organogenesis Holdings Inc. Reports Preliminary Revenue Results for the Fourth Quarter and Fiscal Year 2019
13 janv. 2020 07h00 HE
|
Organogenesis Holdings Inc.
CANTON, Mass., Jan. 13, 2020 (GLOBE NEWSWIRE) -- Organogenesis Holdings Inc. (Nasdaq: ORGO), a leading regenerative medicine company focused on the development, manufacture, and commercialization of...
Organogenesis Holdings Inc. Announces Pricing of Public Offering of Class A Common Stock
21 nov. 2019 22h04 HE
|
Organogenesis Holdings Inc.
CANTON, Mass., Nov. 21, 2019 (GLOBE NEWSWIRE) -- Organogenesis Holdings Inc. (Nasdaq: ORGO), a leading regenerative medicine company focused on the development, manufacture, and commercialization of...
Organogenesis Holdings Inc. Announces Proposed Public Offering of Class A Common Stock
19 nov. 2019 16h01 HE
|
Organogenesis Holdings Inc.
CANTON, Mass., Nov. 19, 2019 (GLOBE NEWSWIRE) -- Organogenesis Holdings Inc. (Nasdaq: ORGO), a leading regenerative medicine company focused on the development, manufacture, and commercialization of...
Organogenesis Holdings Inc. Reports Third Quarter and Nine Months of 2019 Financial Results
12 nov. 2019 16h05 HE
|
Organogenesis Holdings Inc.
CANTON, Mass., Nov. 12, 2019 (GLOBE NEWSWIRE) -- Organogenesis Holdings Inc. (Nasdaq: ORGO), a leading regenerative medicine company focused on the development, manufacture, and commercialization of...
Latest Advanced Wound Care Research from Organogenesis Highlighted at SAWC Fall 2019
11 oct. 2019 16h05 HE
|
Organogenesis Holdings Inc.
CANTON, Mass. and LAS VEGAS, Oct. 11, 2019 (GLOBE NEWSWIRE) -- Organogenesis Holdings Inc. (Nasdaq: ORGO), a leading regenerative medicine company focused on the development, manufacture and...